anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a vaccine capable of inducing a strong and continuous T-cell response, which is useful for treating tumors and chronic viral diseases, allergies and other chronic diseases, in particular.  <P>SOLUTION: Virus-like particles (VLPs) are loaded with immunostimulatory substances, wherein CpG-VLPs loaded with DNA oligonucleotides containing non-methylated C and G (CpG) exhibit remarkably higher immunogenicity than that of their CpG-free counterparts and induce enhanced B- and T-cell responses, in particular. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T-cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to the CpG-loaded VLPs may therefore be suitable vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The present invention relates to a Tujia ethnic minority empirical prescription for treating cardiovascular and cerebrovascular diseases. The present invention is composed of the following medicine of japanese ginseng, fresh gingko leaf, vanilla of fine stalks, tall gastrodis tuber, fresh cephalotaxus fortunei leaf, eucommia bark, notoginseng, gynostemma pentaphylla, red sage root, pungent litse fruit, epimedium, songaria cynomorium herb, wild chrysanthemum, snakegourd peel, rheum palmatum, tuckahoe, chuanxiong rhizome, moschus berezovskii flexor, common selfheal fruit-spike and licorice root. The preparations of the empirical prescription are pulverized into superfine powder and sieved by a sieve of 200 meshes, and the fine powder is used for standby. The preparations of the empirical prescription are decocted and concentrated into extract, capsules are made by mixing the powder and the extract, and the weight of each granule is 0.3g. The empirical prescription is an effective empirical prescription for treating cardiovascular and cerebrovascular diseases, which is handed down through the teachers of a plurality of generation from a plurality of folk old doctors of Tujia ethnic minority. The doctors of Tujia ethnic minority treats hundreds cases of cardiovascular and cerebrovascular diseases according to the empirical prescription, and all receive satisfactory and magical effect. The inventor proves that the prescription treats 2 cases of angina pectoris, 2 cases of congestive heart failure, 3 cases of hypertension, 3 cases of arrhythmia and 1 case of sequelae, and all obtains satisfactory therapeutic effect. The efficiency reaches 100%.
ABSTRACT OF THE DISCLOSURE The preparation of pharmaceutical powder compositions which are directly compressible into tablets, is disclosed.  The disclosed process includes subjecting an aqueous slurry/solution of a pharmaceutically active drug specifically naproxen or naproxen sodium (which slurry may be directly obtained without drying from the synthesis of the drug), alone or in admixture with an aqueous mixture of excipient materials, to a controlled form of spray drying to produce a dry powder of uniform particle size wherein the drug is uniformly dispersed in and coated with the excipients.  The powder can be readily combined with additional dry excipient materials and formed into tablets.  The process provides for substantial savings in the manufacture of the tablets.  The spray dried powder compositions are highly compressible.  Utilizing such spray dried powder compositions, the tablets formed are readily dissolvable and also are stable under normal storage conditions and stress conditions of temperature and relative humidity.
PURPOSE: To report the outcomes of cataract surgery in patients with ocular graft-versus-host disease (oGVHD) using a novel preoperative immunomodulatory regimen in a collaborative subspecialty care setting.
METHODS: Retrospective case series of patients with oGVHD who underwent cataract surgery using a novel preoperative immunomodulatory regimen in a collaborative care setting. A preoperative regimen consisting of pooled human immune globulin 1%, autologous serum 50%, and methylprednisolone 1% eye drops was prescribed. Outcome measures included visual acuity (VA), ocular surface disease index (OSDI) score, lissamine green staining, and complications with a minimum of 2 years of follow-up.
RESULTS: Thirty-five eyes from 20 patients with oGVHD were studied. The mean age was 59 years (range 30-70 years). A healthy comparison group included 35 eyes from 24 patients with a mean age of 63 years (range 44-74 years). At the 2-year follow-up, the mean corneal staining score was 2.3/15, the mean OSDI score was 37.5, and the mean VA was 20/30 (logarithm of the minimal angle of resolution 0.17). The global complication rate was 2.8% at the last follow-up with no difference versus a healthy comparison group.
CONCLUSIONS: A collaborative care model improving ocular surface health before cataract surgery with dry eye and cataract subspecialists can optimize outcomes in patients with oGVHD.
AIM: To assess and verify the effect of the gut microbiome on the susceptibility and complications of type 1 diabetes (T1D).
MATERIALS AND METHODS: To achieve this aim, a two-sample and reverse Mendelian randomization (MR) analysis was conducted. In addition, an external validation study was performed using individual microbiome data of patients with T1D from the gutMEGA datasets and the National Clinical Research Center for Metabolic Diseases. The circulating metabolites facilitated two-sample MR analysis, mediation and multivariable MR analysis to evaluate the direct relationship between the gut microbiome and T1D complications.
RESULTS: The MR analysis results from the discovery and validation phases confirmed that Veillonellaceae can potentially reduce the susceptibility of T1D. In the gutMEGA dataset, the average relative abundance of Veillonellaceae in patients with T1D was 0.66%, compared with 1.09% in the controls. Furthermore, the external validation, which included 60 patients with T1D and 30 matched healthy controls, found that the median relative abundance of Veillonellaceae was also lower than controls at 1.10% (95% CI 0.50%-1.80%). Specifically, the Eubacterium coprostanoligenes group, known for its ability to regulate cholesterol, was significantly associated with a lower risk of developing renal, neurological and ophthalmic complications in T1D. Moreover, high cholesterol in small high-density lipoprotein and cholesteryl esters in high-density lipoprotein were associated with a reduced risk of T1D renal and ophthalmic complications. The mediation and multivariable MR analysis combining cholesterol indicated that the E. coprostanoligenes group is the most dominant factor influencing T1D complications.
CONCLUSIONS: Our findings supported the potential causal effect of gut microbiota on the susceptibility and complications of T1D.
Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
BACKGROUND: Restorative Brain-Computer Interfaces (BCI) that combine motor imagery with visual feedback and functional electrical stimulation (FES) may offer much-needed treatment alternatives for patients with severely impaired upper limb (UL) function after a stroke.
OBJECTIVES: This study aimed to examine if BCI-based training, combining motor imagery with FES targeting finger/wrist extensors, is more effective in improving severely impaired UL motor function than conventional therapy in the subacute phase after stroke, and if patients with preserved cortical-spinal tract (CST) integrity benefit more from BCI training.
METHODS: Forty patients with severe UL paresis (< 13 on Action Research Arm Test (ARAT) were randomized to either a 12-session BCI training as part of their rehabilitation or conventional UL rehabilitation. BCI sessions were conducted 3-4 times weekly for 3-4 weeks. At baseline, Transcranial Magnetic Stimulation (TMS) was performed to examine CST integrity. The main endpoint was the ARAT at 3 months post-stroke. A binominal logistic regression was conducted to examine the effect of treatment group and CST integrity on achieving meaningful improvement. In the BCI group, electroencephalographic (EEG) data were analyzed to investigate changes in event-related desynchronization (ERD) during the course of therapy.
RESULTS: Data from 35 patients (15 in the BCI group and 20 in the control group) were analyzed at 3-month follow-up. Few patients (10/35) improved above the minimally clinically important difference of 6 points on ARAT, 5/15 in the BCI group, 5/20 in control. An independent-samples Mann-Whitney U test revealed no differences between the two groups, p = 0.382. In the logistic regression only CST integrity was a significant predictor for improving UL motor function, p = 0.007. The EEG analysis showed significant changes in ERD of the affected hemisphere and its lateralization only during unaffected UL motor imagery at the end of the therapy.
CONCLUSION: This is the first RCT examining BCI training in the subacute phase where only patients with severe UL paresis were included. Though more patients in the BCI group improved relative to the group size, the difference between the groups was not significant. In the present study, preserved CTS integrity was much more vital for UL improvement than which type of intervention the patients received. Larger studies including only patients with some preserved CST integrity should be attempted.
A 13-year-old girl who had a kidney transplant four weeks prior presented with a 10-day history of fatigue, paleness, and headache. On physical examination, tachycardia and paleness were noted. Laboratory testing was notable for severe anemia and mild leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) test for Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were negative and for parvovirus B19 (PVB19) was positive. Despite lower immunosuppression and administration of intravenous immunoglobulin (IVIG) it persisted for 15 months, and frequent red blood cell transfusions were needed. PVB19 is a less common but significant complication. The patient's clinical course demonstrates the importance of this complication and the challenges in its management. A notable void exists in the literature regarding standardized treatment protocols for PVB19-induced recurrent anemia after kidney transplant. This case indicates the need for further research and consensus to guide effective clinical interventions in similar cases.
Patients will be randomized to muscadine grape extract (MGE). The patients will take 4 capsules by mouth BID (twice daily). Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
Soft tissue filler injections are among the most popular facial rejuvenation methods. Cerebral infarction and ophthalmic artery occlusion are rare and catastrophic complications, especially when facial cosmetic fillers are injected by inexperienced doctors. Radiologists and plastic surgeons need to increase their awareness of the complications associated with fillers, which allows early diagnosis and intervention to improve patient prognosis. Regarding the mechanism by which vascular occlusion occurs after facial filler injections, a retrograde embolic mechanism is currently the predominant theory. Numerous case reports have been presented regarding complications associated with injections of facial aesthetics. However, the small sample sizes of these studies did not allow for an adequate assessment of the clinical and imaging manifestations based on the location of the occlusion and the type of filler, and detailed elaboration of multiple cerebral infarctions is also lacking. Therefore, this study aimed to investigate the clinical and radiological features of severe cerebral and ocular complications caused by cosmetic facial filler injections. In addition, we discuss the pathogenesis, treatment, and prognosis of these patients. The clinical, computed tomography (CT), magnetic resonance imaging (MRI), and digital subtraction angiography (DSA) findings were described and analysed. Radiological examinations are crucial for demonstrating severe complications, and brain MRI is especially strongly suggested for patients with cosmetic filler-induced vision loss to identify asymptomatic cerebral infarctions. Extreme caution and care should be taken during facial injections by plastic surgeons.
Preoperative assessment with questionnaires, Mechanical Temporal Summation, Pain-Pressure Threshold, and heart rate variability. All patients will undergo elective abdominal or laparoscopic hysterectomy. Patients will be assigned to this group if no significant pain is noted during the follow up evaluations at 24 and 48 hours.
The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed "Mirta22," that inhibits the formation of structures which create connections between neurons. It is further based, in part, on the discovery that inhibiting Mirta22 activity by short hairpin RNA was able to restore these structures. Mirta22 was discovered in experiments relating to 22q 11 microdeletions, which have been linked to schizophrenia. Accordingly, the present invention provides for methods of treating schizophrenia comprising administering an agent that inhibits Mirta22 activity. It may also be used in the treatment of other disorders that would benefit from enhanced neural connectivity, including learning and memory disorders.
Patients will undergo assessment with the EORTC QLQ-C30 and QLQ-OGS25 questionnaires. Those patients who undergo local therapy will occur at baseline, months 7-9 within 45 days of local therapy, and one year/time of progression. Those patients who do not undergo local therapy will undergo assessment at baseline, at 6 months, and at one year.
The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.

Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development [see Warnings and Precautions (5.1)] . Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline- class. Most of these patients took medications immediately before going to bed [ see Dosage and Administration (2.1)]. 

Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, and erythema multiforme have been reported. Photosensitivity is discussed above [ see Warnings and Precautions (5.3)]. 

Renal: Rise in BUN has been reported and is apparently dose-related [ see Warnings and Precautions (5.8)]. 

Hypersensitivity reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS). 

Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported. 

Intracranial Hypertension: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline [ see Warnings and Precautions (5.6)] 

Thyroid Gland Changes: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.
Most studies found a lower incidence of systemic and ocular adverse events with fixed combinations than with the unfixed combinations. Fixed combinations are better tolerated than their respective prostaglandin analogue. However, among the most serious side effects induced by PGA are the breaking down of the blood-aqueous barrier (BAB) and the development of cystoids macular edema (CME). Also, timolol maleate drops increase protein concentration in the human and benzalkonium chloride, eye drops preservative induces anterior chamber inflammation. This randomized, masked-observer, prospective clinical trial was approved by the Ethics Committee of the University of Campinas, and it adhered to the tenets of the Declaration Of Helsinki. Written informed consent was obtained from each patient.
The present invention relates to novel specific small molecule inhibitors that block KMT9 methyltransferase activity. In particular, the present invention is concerned with a compound of formula (I) wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 5 , R 6  and L are as defined herein. Further, the present invention is concerned with a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (I). The present invention also relates to a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use in medicine. Yet further, the present invention is concerned with a compound of formula (I) and a pharmaceutical composition comprising a compound of formula (I) for use as inhibitor of KMT9. Finally, the present invention is concerned with a compound of formula (I), wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 5 , R 6  and L are as defined herein, for use in the treatment of cancer selected from the group as defined herein.
PURPOSE:The titled composition obtained by blending a mixture of a bitter drug and an excipient with lecithin or an analog substance thereof. CONSTITUTION:A bitter drug is dissolved in or dispersed into an organic solvent such as chloroform, etc., lecithin or an analog substance thereof is added to the solution or dispersion or the bitter drug is dissolved in or dispersed into water and blended with a solution of lecithin or the analog substance thereof in the organic solvent while stirring to give a blend. The blend is mixed with a powdery excipient (e.g. magnesium aluminate metasilicate, synthetic aluminum silicate, lactose, mannitol, etc.), dried, granulated or made into fine granules to give a preparation composition suppressing bitterness. The blending ratio of the bitter drug, lecithin and the excipient is 1:>=1:>=1 by weight. EFFECT:The bitter drug may be water-soluble or water-insoluble, the method for production is simple and suitable for mass production.
PURPOSE:A hair cosmetic that contains, as an essential component, a dried powder or extract of carrot foliage, thus stimulating surface layers of skins to activate skin cells, thus accelerating hair nourishing, hair growth and depilation inhibition. CONSTITUTION:Foliage of carrot is dried and crushed. The crushed product can be used as an active ingredient. The crushed product is extracted with a lower aliphatic alcohol such as methanol or water at 60-90 deg.C under reflux for 30-80min. The extract is filtered, the filtrate is concentrated under normal or reduced pressure, until the concentration reaches about 30%. The concentrate may be used as such or dried to a pale green powder under reduced pressure. They are low in concentration, but it can be used as such. Or it is purified using n-hexane-water to give a dried powder of high purity. EFFECT:When it is applied for a long period of time, the hair-tonic effect will be remarkable.
This study will evaluate whether using lower doses of contrast dye leads to lower rates of kidney injury compared to current standard of care. In particular, effort will be taken to maintain the total amount of contrast dye below a scientifically-validated threshold calculated on the basis of each participant renal function. Participants will already be scheduled to undergo a PCI. Because a smaller amount of contrast dye will be used, an intravascular ultrasound (IVUS) will be used to help the doctors see and open the blockages in participant's coronary arteries. IVUS is already used to optimize PCI results, but will be used more extensively in this case. The amount of contrast dye received will be tailored on each participant kidney function. Prospectively enrolled patients will be matched with historical controls who underwent PCI with non-intravascular imaging based approach.
PURPOSE OF REVIEW: This review explores the role of the endocannabinoid system (ECS) in regulating energy balance, food intake, and metabolism, with a focus on how ECS dysregulation contributes to obesity. The goal is to provide insights into the mechanisms underlying obesity and its associated metabolic disorders.
RECENT FINDINGS: Recent research indicates that the ECS significantly influences food intake, fat storage, insulin sensitivity, and inflammation, all of which are central to the development and progression of obesity. New research areas include the interaction between the ECS and gut microbiota, circadian rhythms of the ECS, and the impact of genetic and epigenetic factors on ECS function. Interest in the therapeutic potential of targeting the ECS has grown, with earlier treatments like CB1 receptor antagonists showing mixed results in efficacy and safety. Evidence from both animal and human studies highlight the impact of elevated levels of the endocannabinoids anandamide and 2-AG on food intake, insulin resistance, visceral fat accumulation, and metabolic disturbances associated with obesity. The review explores the interaction between the ECS and other physiological systems, including gut-brain communication, circadian rhythms, as well as leptin and ghrelin signaling. Additionally, genetic and epigenetic factors influencing ECS function are examined, emphasizing their contribution to obesity susceptibility. While therapeutic approaches targeting the ECS, particularly CB1 receptor antagonism, have shown potential in managing obesity, the review acknowledges the challenges posed by central nervous system side effects in earlier treatments like rimonabant. However, recent advancements in peripherally restricted CB1 antagonists offer renewed hope for safer and more effective obesity treatments. The review concludes by addressing future research directions and therapeutic strategies to combat this global health challenge.
New utilities for epidermal growth factor (EGF) as a gastrointestinal therapeutic agent are described. In particular, EGF is useful in preventing gastrointestinal colonization by pathogens and in promoting weight gain. As such EGF can be used to treat intestinal infections and increase animal production for example in the agriculture or aquaculture industry. EGF is also useful in increasing the intestinal absorption of immunoglobulins. Inhibition of the epidermal growth factor signalling cascade may be used to prevent uptake of toxic or adverse compounds or to promote weight loss. Therefore, the use of an agent that inhibits the activity of epidermal growth factor to decrease the absorption of substance or decrease weight gain is also described.